Research progress in clinical trials of targeted drugs for gastric cancer

Author: Pazilaiti YASEN ¹ ; Pazilaiti YASEN ² ; Hao YUAN ² ; Hong LU ² ; Ya ZHENG ² ; Yuping WANG ² ; Yongning ZHOU ² ; Pazilaiti YASEN ³ ; Hao YUAN ³ ; Hong LU ³ ; Ya ZHENG ³ ; Yuping WANG ³ ; Yongning ZHOU ³
Author Information

1. First Clinical Medical College of Lanzhou University
2. Department of Gastroenterology, The First Hospital of Lanzhou University
3. Key Laboratory for Gastrointestinal Diseases of Gansu Province, The First Hospital of Lanzhou University
Publication Type:Journal Article
Keywords: Clinical trials; Gastric cancer; Targeted therapeutic drugs
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2021;26(4):454-461
CountryChina
Language:Chinese
Abstract: In the past several years, chemotherapy, as the best treatment option for advanced gastric cancer, however, was associated with adverse events and high resistance rates. Recently, molecular targeted drugs have gradually come into notice of clinical researchers due to the advantages of selectively killing tumor cells and less adverse events. Many clinical trials have confirmed targeted drugs targeting receptor tyrosine kinases combined with chemotherapy drugs could provide more survival benefits and might be effective for the treatment of gastric cancer. This article aims to demonstrate the progress in clinical trials of targeted therapeutic drugs for gastric cancer.